Fulzerasib Tablets (Dupert®) – 150?mg × 112 Tablets per Box Price comparison
$1.00
Fulzerasib (Dupert®) is an orally active KRAS G12C inhibitor, conditionally approved in China for advanced non–small-cell lung cancer (NSCLC) with KRAS G12C mutation. Manufactured by CindaBio, NMPA approved under H20240035 (drug code: 86985200000015). Strictly for laboratory research use only—NOT for clinical or human consumption.
描述
Fulzerasib Tablets Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Fulzerasib Tablets (Dupert®) |
| Dosage & Quantity | 150?mg per tablet × 112 tablets per box |
| Formulation | Film-coated tablet |
| Chinese Approval No. | NMPA H20240035 |
| Product Code | 86985200000015 |
| Manufacturer | (CindaBio) |
| Intended Use | Laboratory research only; not for human use |
Fulzerasib Tablets Overview & Mechanism
Fulzerasib is a covalent KRAS G12C inhibitor, irreversibly binding to the mutant cysteine 12 residue. It blocks KRAS-driven signaling (RAF–MEK–ERK, PI3K–AKT), inducing tumor cell growth arrest and apoptosis—and may also modulate the tumor immune microenvironment pharmaceutical-technology.com+15cancernetwork.com+15pubmed.ncbi.nlm.nih.gov+15synapse.patsnap.com.
Fulzerasib Tablets Research & Clinical Data
-
China Conditional Approval (Aug 2024) for KRAS G12C+ advanced NSCLC after ?1 prior treatment
-
Phase II (NCT05005234): ORR 49.1%, DCR 90.5%, median PFS 9.7?mo; median OS not reached in 116 patients
-
Combination Study (KROCUS): Fulzerasib + cetuximab showed ORR ~80% and DCR ~100%, including CNS activity in brain metastases
Fulzerasib Tablets Research Applications
Perfect for:
-
KRAS G12C molecular studies in vitro/in vivo
-
NSCLC tumor biology and resistance pathways
-
Signal-transduction profiling and biomarker investigations
-
Combo therapy research (e.g., with EGFR inhibitors)
Handling & Storage
-
Store at room temperature (20–25?°C); avoid light and moisture.
-
Handle with standard lab PPE; avoid ingestion or inhalation.
-
Packaging: Sealed blister box—inspect integrity before use.
References
-
China NMPA approval (Aug 2024) firstwordpharma.com+9cancernetwork.com+9english.nmpa.gov.cn+9
-
Phase II trial results delveinsight.com+4jto.org+4firstwordpharma.com+4
-
KRAS inhibition mechanism genfleet.com+13synapse.patsnap.com+13oncpracticemanagement.com+13
-
Fulzerasib + cetuximab combo data cancernetwork.com+15onclive.com+15jto.org+15
Fulzerasib Tablets (Dupert®) – 150?mg × 112 Tablets per Box Price comparison 有 1 个评价
相关产品
-
Rilertinib Mesylate Tablets (Sanrisso®) – 100?mg × 20 Tablets per Bottle
Rilertinib mesylate (Sanrisso®), developed by Nanjing Sanhome Pharmaceutical Co., Ltd., is a third-generation EGFR-TKI approved by China's NMPA (Approval No. H20240020; Drug Code: 86901583000930). Each bottle contains 20 tablets of 100?mg each. Strictly for laboratory research use only—not for clinical or human use. $1.00 -
Abiraterone Acetate Tablets (Hengrui) – 250?mg × 120 Tablets per Bottle Price comparison
Abiraterone acetate is a potent CYP17A1 inhibitor used clinically to suppress androgen synthesis in prostate cancer. Manufactured by Chengdu Shengdi Pharmaceutical Co., Ltd., with China NMPA approval under H20193205 (product code: 86980435000069). This product is for laboratory research and development use only—not for clinical or therapeutic use. $2.00 -
Toremifene Citrate Tablets (Ovry®) – 60?mg
Toremifene citrate (brand name Ovry®), manufactured by Jiangsu Ascend Pharmaceutical Co., Ltd., is a selective estrogen receptor modulator (SERM) approved in China (NMPA No.?H20243050, code?86901425001187). Each box contains 30 tablets (60?mg each) in 3 blister cards (barcode?6953272600284). Strictly for laboratory research purposes only. $1.00 -
Limertinib Tablets 80?mg ×?20 – by Osscon Pharma | Research Use Only (3rd?Gen EGFR?TKI)
Limertinib (OuyiXin®) is a third-generation EGFR tyrosine kinase inhibitor (EGFR?TKI) at 80?mg per tablet, 20 tablets per box, from Jiangsu Osscon Pharmaceutical. Approved by China’s NMPA under H20250004, it targets EGFR T790M?mutated non?small cell lung cancer, including patients with brain metastases.
?? For research use only – Not for human consumption or therapeutic use. $1.00
barras –
Thanks